Treatment Outcomes in Anaplastic Thyroid Cancer
| العنوان: | Treatment Outcomes in Anaplastic Thyroid Cancer |
|---|---|
| المؤلفون: | Danielle Elliott Range, Yvonne M. Mowery, Hannah Williamson, David M. Brizel, Kelsey L. Corrigan, Donna Niedzwiecki |
| المصدر: | Journal of Thyroid Research, Vol 2019 (2019) Journal of Thyroid Research |
| بيانات النشر: | Hindawi Limited, 2019. |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Article Subject, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, lcsh:Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, External beam radiotherapy, Stage (cooking), Anaplastic thyroid cancer, Chemotherapy, lcsh:RC648-665, Performance status, Cumulative dose, business.industry, Medical record, Thyroid, medicine.disease, medicine.anatomical_structure, 030220 oncology & carcinogenesis, business, Research Article |
| الوصف: | Background. Anaplastic thyroid cancer (ATC) is rare, accounting for 1-2% of thyroid malignancies. Median survival is only 3-10 months, and the optimal therapeutic approach has not been established. This study aimed to evaluate outcomes in ATC based on treatment modality. Methods. Retrospective review was performed for patients treated at a single institution between 1990 and 2015. Demographic and clinical covariates were extracted from the medical record. Overall survival (OS) was modeled using Kaplan Meier curves for different treatment modalities. Univariate and multivariate analyses were conducted to assess the relationships between treatment and disease characteristics and OS. Results. 28 patients with ATC were identified (n = 16 female, n = 12 male; n = 22 Caucasian, n = 6 African-American; median age 70.9). Majority presented as Stage IVB (71.4%). Most patients received multimodality therapy. 19 patients underwent local surgical resection. 21 patients received locoregional external beam radiotherapy (EBRT) with a median cumulative dose of 3,000 cGy and median number of fractions of 16. 14 patients received systemic therapy (n = 11 concurrent with EBRT), most commonly doxorubicin (n = 9). 16 patients were never disease free, 11 patients had disease recurrence, and 1 patient had no evidence of disease progression. Median OS was 4 months with 1-year survival of 17.9%. Regression analysis showed that EBRT (HR: 0.174; 95% CI: 0.050–0.613; p=0.007) and surgical resection (HR: 0.198; 95% CI: 0.065–0.598; p=0.004) were associated with improved OS. Administration of chemotherapy was not associated with OS. Conclusions. Anaplastic thyroid cancer patients receiving EBRT to the thyroid area/neck and/or surgical resection had better OS than patients without these therapies, though selection bias likely contributed to improved outcomes since patients who can undergo these therapies tend to have better performance status. Prognosis remains poor overall, and new therapeutic approaches are needed to improve outcomes. |
| وصف الملف: | text/xhtml |
| اللغة: | English |
| تدمد: | 2042-0072 2090-8067 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c8b0535bd96cd32bca84a905ca1bbe9Test https://doaj.org/article/08628e063d644afdb4ff4717ef02dea7Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4c8b0535bd96cd32bca84a905ca1bbe9 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20420072 20908067 |
|---|